Market Summary
USD0.74+0.03
Market Closed4.23%
VXRT Stock Price
VXRT RSI Chart
VXRT Valuation
VXRT Price/Sales (Trailing)
VXRT Profitability
VXRT Fundamentals
VXRT Revenue
VXRT Earnings
Price Action
52 Week Range
0.562.37
(Low)(High)
Last 7 days
-2.4%
Last 30 days
-6.1%
Last 90 days
-23.3%
Trailing 12 Months
-67.9%
VXRT Financial Health
VXRT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for VXRT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-06-26 | Watson W. Mark | acquired | - | - | 7,375 | - |
2023-06-26 | Yedid Robert A. | acquired | - | - | 7,375 | - |
2023-06-26 | Wheadon David E. | acquired | - | - | 7,375 | - |
2023-06-26 | HERON ELAINE J | acquired | - | - | 6,922 | - |
2023-06-26 | Finney Michael J. | acquired | - | - | 7,375 | - |
2023-06-12 | Lee Phillip E | acquired | - | - | 22,500 | chief financial officer |
2023-03-17 | Floroiu Cezar Andrei | acquired | - | - | 367,735 | president, chief exec officer |
2023-03-17 | Cummings James F. | acquired | - | - | 194,350 | chief medical officer |
2023-03-17 | Lee Phillip E | acquired | - | - | 101,652 | chief financial officer |
2023-03-17 | Lee Phillip E | acquired | - | - | 191,652 | chief financial officer |
Which funds bought or sold VXRT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-23 | CTC Alternative Strategies, Ltd. | new | - | 8,249 | 8,249 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | sold off | -100 | -36,175 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -1.19 | 229 | 10,867 | -% |
2023-08-16 | Nuveen Asset Management, LLC | sold off | -100 | -1,680,000 | - | -% |
2023-08-15 | HARBOUR INVESTMENTS, INC. | unchanged | - | -40.00 | 1,102 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 162 | 161,454 | 266,940 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | sold off | -100 | -144,605 | - | -% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -1,864 | - | -% |
2023-08-15 | Rokos Capital Management LLP | new | - | 365,250 | 365,250 | -% |
2023-08-15 | IHT Wealth Management, LLC | reduced | -1.57 | -9,969 | 187,696 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Vaxart
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 07, 2023 | blackrock inc. | 1.3% | 1,928,709 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 5.35% | 7,019,507 | SC 13G | |
| Feb 01, 2023 | blackrock inc. | 6.7% | 8,858,225 | SC 13G/A | |
| Jan 10, 2023 | state street corp | 1.83% | 2,398,264 | SC 13G/A | |
| Mar 10, 2022 | state street corp | 10.39% | 13,072,021 | SC 13G/A | |
| Feb 11, 2022 | state street corp | 8.91% | 11,187,642 | SC 13G/A | |
| Feb 07, 2022 | blackrock inc. | 6.7% | 8,452,420 | SC 13G | |
| Feb 11, 2021 | state street corp | 8.63% | 9,444,967 | SC 13G | |
| Jun 09, 2020 | armistice capital, llc | 19.99% | 16,785,583 | SC 13D/A | |
| May 27, 2020 | armistice capital, llc | 11.3% | 8,400,000 | SC 13D/A |
Recent SEC filings of Vaxart
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 06, 2023 | 8-K | Current Report | |
| Aug 03, 2023 | 8-K | Current Report | |
| Aug 03, 2023 | 10-Q | Quarterly Report | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Jul 26, 2023 | 8-K | Current Report | |
| Jul 10, 2023 | 8-K | Current Report |
Peers (Alternatives to Vaxart)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 4.13% | 21.09% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.16% | 19.51% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -6.80% | -20.18% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.71% | 27.59% | 14.15 | 3.78 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 5.59% | 6.81% | 63.29 | 6.67 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -3.04% | 140.92% | -7.66 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -4.51% | -22.98% | -23.78 | 37.44 | 122.90% | 54.78% |
BEAM | 2.0B | 80.2M | 6.46% | -52.82% | -6.01 | 24.54 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 4.38% | -25.42% | -5.13 | 12.17 | -70.36% | -531.73% |
REPL | 980.2M | 15.3M | -15.63% | 3.04% | -5.4 | 64.02 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | -12.64% | -74.33% | -1.13 | 0.42 | 23.74% | 60.24% |
FATE | 221.7M | - | -17.58% | -90.72% | -1.05 | 1.62 | 116.83% | 16.61% |
SGMO | 146.7M | - | -8.84% | -84.12% | -0.74 | 0.61 | 113.96% | -15.19% |
VXRT | 112.7M | 2.1M | -6.14% | -67.90% | -1.12 | 54.83 | 487.70% | -8.66% |
IBIO | 4.1M | - | -12.28% | -96.10% | -0.05 | 3.21 | - | -129.46% |
Vaxart News
Returns for VXRT
Cumulative Returns on VXRT
-36.7%
7-Year Cumulative Returns
-25.3%
5-Year Cumulative Returns
-55.1%
3-Year Cumulative Returns
Risks for VXRT
What is the probability of a big loss on VXRT?
100%
Probability that Vaxart stock will be more than 20% underwater in next one year
100%
Probability that Vaxart stock will be more than 30% underwater in next one year.
100%
Probability that Vaxart stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does VXRT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Vaxart was unfortunately bought at previous high price.
Drawdowns
Financials for Vaxart
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 90.1% | 2,055,000 | 1,081,000 | 107,000 | 228,333 | 349,667 | 471,000 | 892,000 | 1,174,000 | 1,239,000 | 1,650,000 | 4,046,000 | 7,606,000 | 7,795,000 | 7,848,600 | 7,902,200 | 7,955,800 | 8,009,400 | 8,063,000 | 4,159,000 | 3,152,000 | 3,786,000 |
| Operating Expenses | -4.2% | 111,244,000 | 116,080,000 | 114,694,000 | 107,823,000 | 95,848,000 | 82,488,000 | 73,644,000 | 63,072,000 | 53,475,000 | 46,637,000 | 34,216,000 | 30,041,000 | 27,355,000 | 23,388,000 | 25,647,000 | 22,058,000 | 23,051,000 | 26,352,000 | 25,915,000 | 25,562,000 | 22,272,000 |
| S&GA Expenses | -12.7% | 25,630,000 | 29,353,000 | 29,386,000 | 28,693,000 | 26,775,000 | 22,604,000 | 21,890,000 | 21,262,000 | 20,410,000 | 19,156,000 | 15,202,000 | 11,407,000 | 8,672,000 | 6,151,000 | 6,187,000 | 6,082,000 | 6,301,000 | 6,697,000 | 6,681,000 | 8,555,000 | 7,505,000 |
| R&D Expenses | -1.3% | 81,360,000 | 82,473,000 | 81,054,000 | 76,125,000 | 66,068,000 | 56,879,000 | 48,749,000 | 41,810,000 | 34,017,000 | 28,394,000 | 19,863,000 | 14,563,000 | 13,660,000 | 12,253,000 | 14,540,000 | 15,723,000 | 16,391,000 | 17,696,000 | 17,275,000 | 15,301,000 | 13,167,000 |
| EBITDA | 100.0% | - | -100,985,000 | -101,886,000 | -99,422,000 | -88,233,000 | -75,132,000 | -66,155,000 | - | - | -43,681,000 | -29,272,000 | -21,752,000 | -18,734,000 | -14,926,000 | -14,244,000 | -12,679,000 | -13,768,000 | -17,046,000 | - | - | - |
| EBITDA Margin | 100.0% | - | -144 | -952 | -625 | -245 | -159 | -74.16 | - | - | -26.47 | -7.23 | -2.86 | -2.40 | -1.90 | -1.80 | -1.59 | -1.72 | -2.11 | - | - | - |
| Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 315,000 | 407,000 | 452,000 | 491,000 | 821,000 | 1,471,000 | 2,110,000 |
| Earnings Before Taxes | 6.4% | -100,837,000 | -107,721,000 | -107,691,000 | -104,535,000 | -92,804,000 | -79,475,000 | -70,363,000 | -63,445,000 | -53,942,000 | -46,807,000 | -31,982,000 | -24,367,000 | -21,537,000 | -18,210,000 | -18,155,000 | -16,764,000 | -18,083,000 | -21,329,000 | -17,898,000 | -16,376,000 | -12,001,000 |
| EBT Margin | 100.0% | - | -154 | -1,006 | -657 | -258 | -168 | -78.88 | -54.04 | -43.54 | -28.37 | -7.90 | -3.20 | -2.76 | -2.32 | -2.30 | -2.11 | - | - | - | - | - |
| Net Income | 6.4% | -100,917,000 | -107,797,000 | -107,758,000 | -104,604,000 | -92,878,000 | -79,564,000 | -70,470,000 | -63,567,000 | -54,069,000 | -46,930,000 | -32,220,000 | -24,768,000 | -21,943,000 | -18,603,000 | -18,645,000 | -17,138,000 | -18,426,000 | -21,660,000 | -18,007,000 | -14,180,000 | -9,805,000 |
| Net Income Margin | 100.0% | - | -154 | -1,007 | -657 | -258 | -168 | -79.00 | -54.15 | -43.64 | -28.44 | -7.96 | -3.26 | -2.82 | -2.37 | -2.36 | -2.15 | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -103,620,000 | -104,380,000 | -88,156,000 | -87,104,000 | -74,241,000 | -64,989,000 | -59,828,000 | -53,800,000 | -38,968,000 | -24,973,000 | -17,109,000 | -12,001,000 | -11,947,000 | -13,940,000 | -16,033,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -5.5% | 123 | 130 | 154 | 175 | 181 | 200 | 221 | 241 | 229 | 206 | 153 | 155 | 64.00 | 53.00 | 37.00 | 43.00 | 37.00 | 36.00 | 35.00 | 41.00 | 48.00 |
| Current Assets | -6.0% | 71.00 | 76.00 | 99.00 | 120 | 138 | 154 | 169 | 192 | 189 | 175 | 129 | 136 | 46.00 | 34.00 | 18.00 | 21.00 | 17.00 | 15.00 | 15.00 | 19.00 | 26.00 |
| Cash Equivalents | -10.6% | 43.00 | 48.00 | 46.00 | 51.00 | 91.00 | 123 | 144 | 167 | 165 | 157 | 127 | 133 | 44.00 | 30.00 | 14.00 | 20.00 | 16.00 | 8.00 | 12.00 | 18.00 | 24.00 |
| Net PPE | -3.2% | 14.00 | 14.00 | 16.00 | 12.00 | 9.00 | 8.00 | 7.00 | 5.00 | 4.00 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 |
| Goodwill | 0% | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Liabilities | -6.3% | 38.00 | 40.00 | 43.00 | 53.00 | 38.00 | 34.00 | 34.00 | 36.00 | 29.00 | 30.00 | 29.00 | 23.00 | 24.00 | 21.00 | 24.00 | 24.00 | 21.00 | 24.00 | 24.00 | 25.00 | 25.00 |
| Current Liabilities | -11.5% | 14.00 | 16.00 | 18.00 | 22.00 | 16.00 | 11.00 | 11.00 | 13.00 | 13.00 | 12.00 | 12.00 | 10.00 | 11.00 | 7.00 | 9.00 | 9.00 | 7.00 | 9.00 | 7.00 | 8.00 | 9.00 |
| Shareholder's Equity | -5.2% | 85.00 | 90.00 | 111 | 122 | 143 | 166 | 188 | 205 | 200 | 176 | 123 | 132 | 40.00 | 31.00 | 13.00 | 19.00 | 16.00 | 13.00 | 11.00 | 16.00 | 22.00 |
| Retained Earnings | -6.4% | -374 | -352 | -327 | -303 | -273 | -244 | -219 | -198 | -181 | -164 | -148 | -135 | -126 | -117 | -116 | -110 | -104 | -99.35 | -97.99 | -93.09 | -86.54 |
| Additional Paid-In Capital | 4.0% | 460 | 442 | 438 | 426 | 417 | 411 | 407 | 404 | 381 | 341 | 272 | 267 | 167 | 142 | 130 | 125 | 119 | 111 | 109 | 108 | 108 |
| Shares Outstanding | 12.1% | 152 | 136 | 134 | 128 | 126 | 126 | 126 | 124 | 121 | 115 | 110 | 108 | 68.00 | 61.00 | 22.00 | 13.00 | 11.00 | 7.00 | 6.00 | 6.00 | 5.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 9.0% | -85.70 | -94.13 | -94.78 | -81.44 | -81.09 | -68.35 | -59.83 | -54.78 | -49.77 | -37.13 | -23.75 | -16.78 | -11.85 | -11.64 | -13.09 | -15.00 | -16.03 | -8.61 | -14.55 | -13.55 | -12.69 |
| Share Based Compensation | 3.9% | 14.00 | 13.00 | 14.00 | 13.00 | 12.00 | 11.00 | 9.00 | 6.00 | 5.00 | 6.00 | 4.00 | 4.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Cashflow From Investing | 554.9% | 9.00 | 1.00 | -20.41 | -44.39 | -17.73 | -24.81 | -49.10 | -41.82 | -37.72 | -21.78 | -1.22 | -0.33 | -0.15 | -0.30 | -0.85 | -1.03 | -1.08 | -1.12 | 26.00 | 41.00 | 47.00 |
| Cashflow From Financing | 62.0% | 29.00 | 18.00 | 17.00 | 9.00 | 25.00 | 59.00 | 126 | 130 | 208 | 186 | 138 | 131 | 40.00 | 33.00 | 16.00 | 18.00 | 9.00 | 1.00 | -1.73 | -1.61 | -1.48 |
VXRT Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue from Contract with Customer, Including Assessed Tax | $ 1,358 | $ 0 | $ 2,033 | $ 85 |
| Operating expenses: | ||||
| Research and development | 18,813 | 19,926 | 38,435 | 38,129 |
| General and administrative | 5,598 | 9,321 | 12,223 | 15,979 |
| Total operating expenses | 24,411 | 29,247 | 50,658 | 54,108 |
| Operating loss | (23,053) | (29,247) | (48,625) | (54,023) |
| Other income (expense): | ||||
| Interest income | 711 | 157 | 1,353 | 192 |
| Non-cash interest expense related to sale of future royalties | (188) | (323) | (366) | (663) |
| Foreign exchange loss, net | (1) | (2) | (4) | (2) |
| Loss before income taxes | (22,531) | (29,415) | (47,642) | (54,496) |
| Provision for income taxes | 19 | 15 | 48 | 35 |
| Net loss | $ (22,550) | $ (29,430) | $ (47,690) | $ (54,531) |
| Net loss per share - basic and diluted (in dollars per share) | $ (0.16) | $ (0.23) | $ (0.35) | $ (0.43) |
| Shares used to compute net loss per share - basic and diluted (in shares) | 139,594,238 | 126,428,298 | 137,403,416 | 126,111,777 |
| Comprehensive loss: | ||||
| Net loss | $ (22,550) | $ (29,430) | $ (47,690) | $ (54,531) |
| Unrealized gain (loss) on available-for-sale investments, net of tax | 46 | (100) | 275 | (335) |
| Comprehensive loss | (22,504) | (29,530) | (47,415) | (54,866) |
| Non Cash Royalty Revenue [Member] | ||||
| Revenue from Contract with Customer, Including Assessed Tax | 30 | 0 | 308 | 85 |
| Grant [Member] | ||||
| Revenue from Contract with Customer, Including Assessed Tax | $ 1,328 | $ 0 | $ 1,725 | $ 0 |
VXRT Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash, cash equivalents and restricted cash | $ 43,277 | $ 46,013 |
| Short-term investments | 24,628 | 49,704 |
| Accounts receivable | 29 | 20 |
| Prepaid expenses and other current assets | 3,327 | 3,714 |
| Total current assets | 71,261 | 99,451 |
| Property and equipment, net | 13,918 | 15,585 |
| Right-of-use assets, net | 26,804 | 25,715 |
| Intangible assets, net | 4,654 | 5,020 |
| Goodwill | 4,508 | 4,508 |
| Other long-term assets | 1,508 | 3,568 |
| Total assets | 122,653 | 153,847 |
| Current liabilities: | ||
| Accounts payable | 4,199 | 5,514 |
| Deferred grant revenue | 275 | 2,000 |
| Other accrued current liabilities | 6,050 | 8,084 |
| Current portion of operating lease liability | 2,430 | 2,228 |
| Current portion of liability related to sale of future royalties | 929 | 95 |
| Total current liabilities | 13,883 | 17,921 |
| Operating lease liability, net of current portion | 18,566 | 19,477 |
| Liability related to sale of future royalties, net of current portion | 4,869 | 5,621 |
| Other long-term liabilities | 262 | 231 |
| Total liabilities | 37,580 | 43,250 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock: $0.0001 par value; 250,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 152,016,238 shares issued and 151,982,992 shares outstanding as of June 30, 2023 and 134,199,429 shares issued and outstanding as of December 31, 2022. | 15 | 13 |
| Additional paid-in capital | 459,912 | 437,992 |
| Treasury stock at cost, 33,246 shares and none as of June 30, 2023 and December 31, 2022, respectively | (31) | 0 |
| Accumulated deficit | (374,799) | (327,109) |
| Accumulated other comprehensive loss | (24) | (299) |
| Total stockholders’ equity | 85,073 | 110,597 |
| Total liabilities and stockholders’ equity | $ 122,653 | $ 153,847 |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.